Literature DB >> 26403483

CTLA-4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population--a prospective study.

K Tupikowski1, A Partyka2, A Kolodziej1, J Dembowski1, P Debinski1, A Halon3, R Zdrojowy1, I Frydecka2, L Karabon1,2.   

Abstract

Polymorphisms in co-stimulatory genes are associated with susceptibility to several malignances such as breast cancer, cervical cancer and chronic lymphocytic leukemia, but have been scarcely investigated in renal cell cancer (RCC). A total of 310 RCC patients and 518 controls were genotyped for single-nucleotide polymorphisms (SNPs) in the CTLA-4 and CD28 genes: CTLA-4c.49A>G (rs231775), CTLA-4g.319C>T (rs5742909), CTLA-4g.*6230G>A (CT60; rs3087243), CTLA-4g.*10223G>T (Jo31; rs11571302), CD28c.17+3T>C (rs3116496) and CD28c.-1042G>A (rs3181098). The distribution of the alleles, genotypes and haplotypes in the CTLA-4 and CD28 genes were similar in the RCC patients and in the controls. However, among the patients with a clear cell RCC (CCRCC), the G allele carriers of CT60 and Jo31 SNPs were overrepresented, and the overrepresentation became significant for the carriers of CT60[G] allele in CCRCC patients with necrosis in the primary tumor (P = 0.046). The CTLA-4c.49A>G[A]/CTLA-4g.319C>T[C]/CT60[A]/Jo31[T]/CD28c.17+3T>C[T]/ CD28c.1042G>A[G] haplotype was associated with an approximately threefold increased risk of primary tumor necrosis in CCRCC patients (P corrected = 0.0000007) and with the advanced stage of disease (IV) (P corrected = 0.001). When stratified by gender, CD28c.-1042G>A[GG] genotype was more frequent in the female CCRCC patients compared with healthy women (P = 0.042). Polymorphisms in the CTLA-4 and CD28 genes, in particular considered together as haplotypes, were associated with increased risk of CCRCC, especially with necrosis and with the advanced stage of disease. The CD28c.-1042G>A SNP modulates the risk of CCRCC in women. These findings indicate that the associations of the CTLA-4 and CD28 polymorphisms with the risk of renal cancer are worth further study in a larger group of patients.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD28; CTLA-4; polymorphisms; renal cancer

Mesh:

Substances:

Year:  2015        PMID: 26403483     DOI: 10.1111/tan.12671

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  5 in total

1.  Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Authors:  Lidia Karabon; K Tupikowski; A Tomkiewicz; A Partyka; E Pawlak-Adamska; A Wojciechowski; A Kolodziej; J Dembowski; R Zdrojowy; I Frydecka
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

2.  Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.

Authors:  Hongyuan Wan; Hangsheng Zhou; Yanyan Feng; Yongquan Chen; Lijie Zhu; Yuanyuan Mi
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  The association between CD28 gene rs3116496 polymorphism and breast cancer risk in Chinese women.

Authors:  Yuxiang Yan; Xianbo Zhang
Journal:  Biosci Rep       Date:  2017-12-12       Impact factor: 3.840

Review 4.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

5.  Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.

Authors:  Hanaa Hardi; Rahma Melki; Zouhour Boughaleb; Tijani El Harroudi; Souria Aissaoui; Noureddine Boukhatem
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.